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Abstract
Background: Obstructive sleep apnoea (OSA) is very common in patients with type 2 diabetes (T2D). We and
others have shown that OSA was associated with diabetes-related microvascular complications in patients with T2D
in cross-sectional and longitudinal studies and that compliance with continuous positive airway pressure (CPAP)
reduced the progression of microvascular complications. Hence, we hypothesised that adequate CPAP reduces the
development of microvascular complication in patients with T2D.
Methods: SLEEP T2D is a cohort study with embedded feasibility, open-label, parallel-arm, randomised control trial
(RCT) over 2 years. The primary aim is the feasibility of conducting a definitive RCT assessing the impact of CPAP on
chronic kidney disease and other microvascular complications in patients with T2D. The main parameters are to
assess willingness of participants to be randomised, follow-up rates, CPAP adherence/compliance, to optimise the
choice of outcome measures for a substantive trial, and to identify the parameters for sample size calculations. The
secondary aims of the study are related to the impact of CPAP, sleep-related disorders, and sleep chronotype on a
variety of diabetes-related end points. The study participants were recruited from the T2D services in multiple NHS
trusts across England. The main exclusion criteria for the cohort study are as follows: T1D, eGFR < 15 mL/min/1.73
m2, known OSA, active malignancy or chronic kidney disease from reasons other than diabetes, pregnancy,
professional drivers, and a history of falling asleep whilst driving within last 2 years. The main exclusion criteria from
the RCT were as follows: Apnoea-Hypopnoea Index < 10 and Epworth Sleepiness Score ≥ 11. Study participants
were extensively phenotyped clinically and biochemically. The OSA diagnosis was based on multichannel portable
device (ApneaLink AirTM, Resmed).
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Discussion: The feasibility RCT will help us design the future RCT to assess the impact of CPAP on diabetes-related
microvascular complications. The cohort study will generate preliminary data regarding the impact of sleep quality,
duration, and chronotype on diabetes-related outcomes which could lead to further mechanistic and interventional
studies.
Trial registration: ISRCTN, ISRCTN12361838. Registered 04 April 2018, Protocol version: v5.0 02.12.19.
Keywords: Obstructive sleep apnoea, Type 2 diabetes mellitus, Continuous positive airway pressure, Randomised
control trial, Chronic kidney disease, Nephropathy, Neuropathy, Retinopathy, Sight-threatening retinopathy, Diabetic foot
Background
Obstructive sleep apnoea
Obstructive sleep apnoea (OSA) is a chronic disorder
characterised by complete or partial collapse of the
upper airway during the sleep, which results in recurrent
cyclical changes in oxygen saturations (de- and re-
saturations), heart rate, blood pressure, and intrathoracic
pressure [1]. In addition, OSA is characterised by hypox-
emia, fragmented sleep, and increased sympathetic ner-
vous activity [2, 3].
Earlier estimates of OSA prevalence were 2–4%, but
with increasing prevalence of obesity, OSA prevalence
has also increased [4, 5]. The Wisconsin sleep study
showed that 24% of men and 9% of women had OSA
(defined as an Apnoea-Hypopnoea Index (AHI) > 5
events/h) and 9% of men and 4% of women had moder-
ate to severe OSA (AHI ≥15 events/h) [6]. More re-
cently, the prevalence of OSA (AHI ≥ 15 events/h) was
estimated to be 17% and 9% in men and women aged
50–70 years [7].
Obstructive sleep apnoea and type 2 diabetes mellitus
OSA is an established independent risk factor for inci-
dent type 2 diabetes (T2D) [8–10], and more recently
T2D has been shown to be associated with increased risk
of OSA compared to appropriately matched population
without diabetes and after adjustments for potential con-
founders [11]. Hence, unsurprisingly, multiple studies
showed a high prevalence of OSA in patients with T2D
(23–86%) [12–17] with prevalence being higher in White
Europeans compared to South Asians [18]. Our previous
work demonstrated an OSA prevalence of 65% in pa-
tients with T2D [15]. In addition, the severity of OSA is
independently associated with worsening glycaemic con-
trol in patients with T2D [19].
Diabetes-related microvascular complications
Diabetes-related microvascular complications (foot, kid-
ney, eyes, and neuropathy) have significant impact on
patients with T2D and are associated with increased
morbidity and mortality [20]. In addition, most of the fi-
nancial burden of diabetes in the NHS is due to its com-
plications (the cost of treating diabetes complications is
expected to be £13.5 billion by 2035/36) [21]. As a re-
sult, there is significant interest in reducing microvascu-
lar complications to reduce the health and economic
burden of diabetes. Therefore, there is an interest in bet-
ter understanding the pathogenesis of diabetes-related
complications in order to develop new treatment strat-
egies and reduce the burden of diabetes on patients,
society, and the NHS.
Hyperglycaemia induced oxidative and nitrosative
stress are essential steps in the pathogenesis of micro-
vascular complications resulting in DNA damage, exces-
sive poly (ADP-ribose) polymerase (PARP) activation,
and inhibition of glyceraldehyde 3-phosphate dehydro-
genase resulting in activation of aldose reductase, pro-
tein kinase C (PKC), the hexosamine pathway, and
advanced glycation end products (AGE), all of which re-
sult in endothelial and microvascular dysfunction result-
ing in microvascular complications [22–24]. Data from
people without diabetes has shown that OSA can result
in similar molecular consequences to those of hypergly-
caemia including increased oxidative and nitrosative
stress, activation of PKC and AGE production, increased
inflammation, and endothelial dysfunction [25–45]. Our
previous work has expanded those findings to patients
with T2D; OSA and nocturnal hypoxemia were associ-
ated with nitrosative stress, oxidative stress, PARP acti-
vation, and impaired microvascular regulation in
patients with T2D and OSA compared to those with
T2D only [15, 46]. Therefore, it is plausible that OSA
might aggravate or contribute to the development of
microvascular complications.
Obstructive sleep apnoea and microvascular
complications in type 2 diabetes
Cross-sectional studies showed that diabetes-related
chronic kidney disease (CKD), peripheral neuropathy
(PN) and sight-threatening retinopathy (STR) were more
common in patients with OSA and T2D compared to
those with T2D alone despite adjustment for a wide
range of variables [15, 46, 47].
After a follow-up of 2.5 years, the decline in estimated
glomerular filtration rate (eGFR) (based on the 4-
variable MDRD equation) was greater in patients with
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T2D and OSA compared to patients with T2D only [46,
47]. Baseline OSA and AHI were independent predictors
of study-end eGFR after adjustment for baseline eGFR,
age, obesity, diabetes duration, medications, and other
confounders [46].
OSA was also an independent predictor of progression
to pre-proliferative/proliferative STR after adjustment
over a 5-year follow-up period [47]. More recently, our
team found in a cohort matched controlled population-
based study from the UK that the risk of developing car-
diovascular disease, foot disease, diabetic PN, CKD, and
death in patients with T2D and OSA was greater than
those with T2D but without OSA (data undergoing peer
review).
Observational data showed that 3 months’ treatment with
continuous positive airway pressure (CPAP) statistically sig-
nificantly increased the eGFR and decreased the serum cre-
atinine levels in patients with OSA [48]. Our observational
data also showed that patients with T2D and OSA who
were compliant with CPAP had less development of prolif-
erative retinopathy over 5 years and less decline in eGFR
over 2.5 years compared to those non-compliant with
CPAP or with mild OSA, despite lack of significant differ-
ences in participants’ characteristics between those compli-
ant and non-compliant with CPAP [46, 47].
Taken together, these data suggest that OSA could po-
tentially be a modifiable risk factor for the development
and/or worsening of microvascular complications in pa-
tients with T2D. Hence, randomised controlled trials
(RCTs) will be needed to further explore these findings.
Methods/design
SLEEP T2D is an observational cohort study with em-
bedded feasibility RCT. Participants are recruited to the
RCT from the baseline population of the cohort study.
The overall study design is summarised in Fig. 1. The
RCT is an open-label, randomised controlled, parallel
arm, clinical trial of patients with T2D and OSA. Partici-
pants will be randomised in a 1:1 ratio to either CPAP
or no CPAP for 2 years. The observational cohort study
will also run over up to 2 years and will include all pa-
tients who consented to the study regardless of OSA sta-
tus or randomisation status. Patients will be recruited to
the RCT based on OSA being diagnosed by the baseline
sleep study. Patients who are not randomised and are in
the cohort will continue to be in the cohort and will not
be randomised even if they develop OSA during the
follow-up.
All participants are recruited and followed up at their
local OP clinic. Participants’ routine care is not adjusted
Fig. 1 Participants pathway through the study. ESS, Epworth Sleepiness Scale; AHI, Apnoea-Hypopnoea Index; RCT, randomised control trial,
CPAP, continuous positive airway pressure
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in this study. All participants will receive their routine
health care in their local centres for the whole duration
of the study. Scoring of the sleep studies and CPAP initi-
ation and follow-up were performed by a sleep physiolo-
gist (MN) and was supported by a senior sleep




The primary aim of this study (SLEEP T2D) is to assess
the feasibility of running a definitive RCT in patients
with T2D and OSA, randomising participants to CPAP
vs. no CPAP. The overall aim of the substantive RCT
would be to determine the impact of OSA treatment
(CPAP) on the progression of CKD and microvascular
complications in patients with T2D.
The reason for not conducting a substantive RCT
straight away is that we want to ensure that we can meet
the pre-defined criteria (listed below) or understand
what may need to be amended before proceeding to a
full RCT; in particular, we want to specifically examine
acceptability of randomisation to patients, the ability to
obtain enough follow-up data, and the ability to achieve
high CPAP compliance. Poor compliance with CPAP is
very common in real life as well as in research settings
[49], and this could undermine the outcome of the fu-
ture RCT, hence we want to examine whether we can
achieve high compliance with CPAP (see details below)
and learn of what may be needed to achieve our targets.
Patients with moderate to severe OSA are recom-
mended to be treated with CPAP in the UK if they are
symptomatic, particularly if they have excessive daytime
sleepiness (EDS) [50]. Therefore, randomising patients
with EDS to no CPAP would raise ethical concerns. To
avoid this, the Epworth Sleepiness Scale (ESS) will be
used to assess the presence of EDS. Patients with EDS
(ESS ≥ 11) will be excluded from the RCT and their gen-
eral practitioner and/or diabetologist will be informed as
these patients are likely to require treatment. Patients
who have OSA without EDS will be included in the RCT
if they meet the RCT inclusion/exclusion criteria (please
see below). Excluding patients with ESS ≥ 11 is more
stringent than other CPAP RCTs in the field of OSA in
order to maintain patient safety [51–53].
An AHI of ≥ 10 was chosen as the cut off for random-
isation as we felt patients will not tolerate CPAP with
lower values of AHI and because some other CPAP trials
used the same cut off for randomisation [54–56].
The control arm is ‘no CPAP’. The choice of no CPAP
over sham CPAP was a pragmatic one. Using sham
CPAP is more expensive and more time and resource
consuming. It is difficult to blind patients or the asses-
sors to the treatment allocation as patients on sham
CPAP will still have symptoms related to OSA. This lack
of effect can be associated with treatment non-
compliance, which will also affect outcomes. Further-
more, although sham CPAP produces much less pres-
sure than active CPAP, this pressure is not 0 and hence
might still have some physiological function [57, 58].
The use of no CPAP rather than sham CPAP is common
in CPAP trials [57–59].
The study duration of 2 years is because many of the
secondary outcomes such as renal function or neur-
opathy do not change significantly over short period of
times.
The rationale for the cohort study
Sleep T2D will collect a large amount of data on study
participants whether they are randomised or not. Hence,
in addition to the RCT, Sleep T2D will include a cohort
study assessing the impact of sleep-related parameters
on diabetes-related outcomes (see outcomes below).
Whilst multiple studies have shown the relationship be-
tween sleep quality, duration, and chronotype with
haemoglobin A1c (HbA1c) [60–65] and one recent study
eGFR [66], there are no published cohort studies at the
time of writing the protocol that assessed the impact of
sleep quality, duration, and chronotype and EDS on gly-
caemic control and other diabetes-related outcomes in
people with T2D. We hypothesised that short sleep dur-
ation, poor sleep quality, and later chronotype are asso-
ciated with worse diabetes-related outcomes. Sleep T2D
will examine these potential associations longitudinally.
In addition, the data will allow us to explore the interac-
tions between different sleep parameters/disorders and
T2D-related outcomes. The findings of the cohort study
might lead to future RCTs and all the outcomes of the
cohort study are either secondary or tertiary (see below).
Study participants
Patients with T2D will be recruited from the outpatient
diabetes departments of 13 NHS trusts in England.
Inclusion and exclusion criteria
The following are the inclusion criteria for the observa-
tional cohort study:
1) Are ≥ 18 years old,
2) Diagnosis of T2D,
3) eGFR ≥ 15 mL/min/1.73 m2 in last 12 months.
The following are the exclusion criteria for the obser-
vational cohort study:
1) History of T1D,
2) Known OSA, active malignancy or CKD from
reasons other than diabetes,
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3) Receiving chemotherapy, immunosuppressant
drugs, or home oxygen treatment,
4) History of recurrent hospital admissions due to
infective exacerbation of a respiratory condition,
5) Received contrast imaging within the last 2 months,
6) Pregnancy,
7) Intending to undergo bariatric surgery during the
study duration,
8) Unable to comply with the study protocol,
9) Unable to give informed consent,
10) Professional drivers, operators of heavy machinery,
and/or working at high altitude,
11) History of falling asleep whilst driving within last
two years.
Participants will be considered eligible for randomisa-
tion if they:
1) Are willing to be randomised to CPAP or no CPAP,
2) Have an ESS < 11 (as completed by the participant
during the baseline assessment),
3) Have an AHI ≥ 10*.
Potential participants will be excluded from the RCT if
they have:
1) A resting oxygen saturation < 90%*, or
2) Central apnoea index > 15/h*
*as detected during the baseline home-based sleep
study using multichannel portable device.
When in doubt regarding eligibility for randomisation
and/or the sleep recordings, the cases will be discussed
with the study sleep physician (AA) and senior sleep
physiologist (BC) to ensure patient safety is not
compromised.
Randomisation
Eligible participants for the RCT will be randomised in a
1:1 ratio to either CPAP or no CPAP. A stratified block
randomisation method will be used within the compu-
terised randomisation system to ensure balance in the
treatment allocation over the following variables: ethni-
city (White Europeans, others), gender (male, female),
and severity of OSA (AHI 10– < 15, ≥ 15).
RCT Treatment arms
Intervention arm: Participants that are allocated to the
CPAP arm will be provided with a CPAP machine
(ResMed Airsense 10 Autoset™). Each patient in the
CPAP arm will be given an appropriate mask, connect-
ing hose, a heated humidifier, and all the necessary
accessories to operate the CPAP equipment for the dur-
ation of the trial. This machine features built-in wireless
connectivity capability to monitor compliance remotely
via a secured website, AirView (AV); AutoRamp™ with
sleep onset detection; expiratory pressure relief and
Easy-Breathe technology, allowing a suitably qualified
person to remotely change settings to improve patient
compliance and comfort if required.
Control arm: Νο treatment.
Outcome measures
The primary outcome measures are to:
1) Assess willingness of participants to be randomised,
2) Assess willingness of clinicians to recruit
participants,
3) Assess follow-up rates and adherence/compliance rates,
4) Provide data to inform the sample size for a
substantive trial,
5) Optimise the choice of outcome measures for a
substantive trial.
The secondary outcome measures are:
To assess the impact of CPAP in patients with T2D
on:
1) Measures of CKD including eGFR, cystatin-C, and
albumin/creatinine ratio (ACR),
2) Diabetes-related neuropathy (including painless and
painful peripheral neuropathy, cardiac autonomic
neuropathy, and peripheral autonomic neuropathy),
3) Diabetes-related retinopathy and maculopathy,
4) Metabolic parameters such as weight, HbA1c, blood
pressure, and lipids profile.
The changes in the above-listed diabetes-related endpoints
will be described as changes in the values of continuous var-
iables or changes in categories for categorical variables.
The tertiary outcome measures are:
1) To explore the utility of different biomarkers in
screening for OSA in patients with T2D,
2) To explore the mechanisms via which CPAP might
have an impact on diabetes-related complications,
3) To assess the relationship between other sleep-
related disorders, metabolic parameters, and vascu-
lar disease in patients with T2D,
4) To build up a cohort of well characterised patients
for longitudinal follow-up to inform us about the
natural history of OSA, sleep-related disorders, and
diabetes-related complications.
Feasibility criteria
1) Recruiting the proposed sample size within the
planned time frames,
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2) Meeting the proposed time frames in regard to
interpreting the sleep assessments and initiating
patients on treatment (within 8 weeks from the
registration),
3) Achieving a follow-up rate ≥ 80% for randomised
patients,
4) Achieving a CPAP usage ≥ 4 h/night on ≥ 70% of
nights in ≥ 80% patients randomised to CPAP
treatment,
5) Generating a mean and standard deviation
regarding the predicted response to the intervention
to allow sample size calculations for a substantive
RCT.
Compliance initiation and monitoring
CPAP will be initiated by the sleep physiologist (MN) at
a place that is convenient to the patients (at home for
example). Prior to initiating CPAP, the physiologist will
discuss the benefits of CPAP treatment and will provide
explanation about the technical aspects and usage of the
device. MN will contact the patients by telephone 2–3
times during the first week of CPAP use to troubleshoot
any challenges.
Adequate compliance in this trial will be defined as an
average usage of CPAP > 4 h/night on 70% of nights.
Compliance will be monitored using the manufacturer’s
AirView remote monitoring, whilst only the study sleep
technician and chief investigator will have permission to
remotely access and change CPAP settings via the se-
cured website using AirView. The sleep technician and
chief investigator will view sleep data of all patients re-
motely twice weekly on average and will identify those
using CPAP < 4 h. Patients will be called if CPAP usage
is < 4 h per night to determine the cause and any action
required to enhance compliance.
Study assessments and follow-up
Following consent and checking eligibility, participants
will have a baseline assessment (0 months), in which the
following data will be collected:
Physical examination:
– Height and weight measurements,




– Random lipid profile,
– Creatinine,
– Urinary ACR.
– A serum sample for the measurement of cystatin C
will also be taken.
Quality of life:
– Short Form Health Survey (SF-12) questionnaire.
Peripheral neuropathy:
– Michigan Neuropathy Screening Instrument (MNSI)
questionnaire,
– Short Form McGill Pain Questionnaire (SF-MPQ),
– Selected sites will also perform Sudoscan and
Cardiac autonomic neuropathy (CAN) assessments.
Sleep apnoea, habits, duration, and quality:
– One-night home-based sleep assessment using a
portable multi-channel respiratory device approved




– Morningness-Eveningness Questionnaire (MEQ),
– Pittsburgh Sleep Quality Index (PSQI).
Retinopathy
The evaluation of retinopathy will be assessed using 2
× 45 degrees’ digital retinal images per eye as per the
English National Screening program guidelines [67].
The examinations and the questionnaires for the base-
line assessment are described in the Supplementary File
1 in detail.
All patients in the RCT and cohort study will be con-
tacted every 6 months by phone to enhance follow-up
rates and to collect data about any new relevant develop-
ments and ensure continuation of consent and patient
safety. Those in CPAP will be contacted more often as
described above depending on compliance and also for
the short term after CPAP initiation. The same data with
the baseline visit will be collected at study-end (at up to
2 years from baseline). Table 1 summarises the proced-
ure from registration to follow-up visits.
Statistical considerations and rational
Since this is a feasibility RCT, no formal sample size cal-
culations have been undertaken as the study is not de-
signed or powered to detect a statistically significant
difference in efficacy between the two treatment arms,
which is consistent with guidance from the National In-
stitute for Health Research (NIHR) in the UK [68].
As the cohort study is independent of the RCT’s
aim, it is intended to be hypothesis generating, and
no formal sample size calculation has been under-
taken for it. One hundred forty patients will be ran-
domised in the RCT. At least 60% of patients
attending a secondary care diabetes clinic could be
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eligible for recruitment and based on the results of
our previous work, showing an OSA prevalence of
65% in patients with T2D [15], it is expected that up
to 500 patients will need to be registered into the ob-
servational cohort study and assessed for OSA to
reach 140 participants with confirmed OSA eligible
for randomisation in the RCT.
Statistical analysis
The primary comparison groups will be composed of
those treated with CPAP versus those not receiving
CPAP. In the first instance, all analyses will use the
intention to treat principle.
Analyses of outcomes will primarily take the form of
simple descriptive statistics (e.g. proportions and
Table 1 Outcome measures and assessments
Summary of assessments Trial period












Registration and treatment allocation
Main eligibility assessed x
Study consent x
Registration onto study x
Additional eligibility for RCT assessed x
Consent RCT x
Treatment allocation/randomisation x
GP letter(s) x x
Intervention (if receiving)
CPAP Initiation (CPAP use continues until 2 years) x
Assessments




Review of medication x x
Review of past medical history x
Physical exam and blood pressure:
Height, weight , blood pressure (standardised)
x x
Circumferences hip, waist, neck (standardised) x x
Routine biochemistry: lipid profile and HBA1c, eGFR and creatinine,
plasma urea, electrolytes and creatinine, ACR
xa xa
Additional blood for future biomarker studies;
Additional blood for serum cystatin C
x x
Peripheral neuropathy: MNSI; SF-MPQ; vibration perception threshold;
monofilament and Neuropad test
x x
SUDOSCAN and CAN assessment x selected sites x selected sites
Retinopathy x x
Sleepiness and obstructive sleep apnoea risk:
One night home-based sleep assessment
x x
ESS and Berlin Questionnaire x x
Sleeping habits, duration and quality:
MEQ and PSQI
x x
6 monthly follow-up form x
SAE monitoring (SAE forms) x x x x
RCT randomised control trial, CPAP continuous positive air pressure, SF-12 Short Form Health Survey, HBA1c haemoglobin A1c, eGFR estimated glomerular filtration
rate, ACR albumin/creatinine ratio, CAN cardiac autonomic neuropathy, ESS Epworth Sleepiness Scale, PSQI Pittsburgh Sleep Quality Index, SAE serious adverse event
aIf performed within 3 months of visit (within 12 months for ACR) then previously recorded measurements can be used
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percentages, means and standard deviations) and, where
appropriate, point estimates of effect sizes (e.g. mean dif-
ferences and relative risks) and associated 95% confi-
dence intervals.
For the tertiary objectives, the full cohort will be
analysed.
Monitoring
Safety reporting (RCTs only)
The collection and reporting of adverse events (AEs) will
be in accordance with the UK Policy Framework for
Health and Social Care Research and the requirements
of the Health Research Authority. The investigator will
assess the seriousness and causality (relatedness) of all
AEs experienced by the trial participant. Any trial-
related serious AEs will be reported by the investigator
or delegate on a trial-specific serious AE form to the Bir-
mingham Clinical Trial Unit trials office, no later than
24 h after first becoming aware of the event.
Independent committee
A joint study oversight committee that comprises both
Study Steering Committee and Data Monitoring Com-
mittee functions will be engaged for this trial. The role
of the study oversight committee is to provide the over-
all supervision of the trial, monitor trial progress and ad-
vice on scientific credibility.
Ethics approval and consent to participate
Patients will be approached by their clinical care teams
and then consent for the cohort study will be obtained
and baseline assessments performed by appropriately
trained research nurses as per the delegation log. If eli-
gible for the RCT, a further informed consent will be ob-
tained by post or in person and the randomisation visit
can be performed either at their local research centre or
by telephone.
The study will be performed in accordance with the
recommendations guiding physicians in biomedical re-
search involving human subjects, adopted by the 18th
World Medical Association (WMA) General Assembly,
Helsinki, Finland, 1964, amended by the 48th WMA
General Assembly, Somerset West, Republic of South
Africa, 1996.
The trial will be conducted in accordance with the Re-
search Governance Framework for Health and Social
Care, the applicable UK Statutory Instruments (which
include the Data Protection Act 2018 and Human Tissue
Act 2008), the EU General Data Protection Regulation
2018, and the principles of Good Clinical Practice. Writ-
ten informed consent will be provided by all patients
prior to any trial-related procedures. Participants will be
free to withdraw from the trial at any time without any
effect on their standard of care.
Discussion and conclusions
SLEEP T2D is an observational cohort study with a sub-
set of participants included in a feasibility RCT of a CE
marked medical device used within its intended purpose.
The outcome of this study will guide the design of a fu-
ture RCT that might have significant impact on reducing
the burden of T2D microvascular complications. In
addition, the observational cohort study will provide
novel hypothesis generating data that might lead to fu-
ture RCTs to improve diabetes-related outcomes.
This study has several strengths including its novelty
and the multicentre and randomised design. It also uses
a pragmatic approach to CPAP treatment and the study
population are very well characterised and phenotyped.
However, the study has its limitations, including the un-
blinded design, but most of the study outcomes are not
based on patient reporting and the decision not to have
sham CPAP was pragmatic and discussed above. The
study has now finished recruitment and all patients are
currently in follow-up. As a result of the disruption
caused by COVID-19 pandemic and the focus on
COVID-19 research by the participating NHS trusts and
the need to move the feasibility RCT forward to apply
for funding for the full RCT (if applicable), we have sub-
mitted an amendment that has been approved to collect
study-end data as soon as it is practical and allowed by
the NHS trusts. This means that for some study partici-
pants, the study-end visit will be after less than 2 years
follow-up and for others it will be more than 2 years.
We aim to start the study end visits from January 2021
in the centres that allow us. We expect all patients to
have at least 1 year follow-up by the time they have the
study end visit.
Abbreviations
OSA: Obstructive sleep apnoea; AHI: Apnoea-Hypopnoea Index; T2D: Type 2
diabetes mellitus; PARP: Poly (ADP-ribose) polymerase; PKC: Protein kinase C;
AGE: Advanced glycation end products; CKD: Chronic kidney disease;
PN: Peripheral neuropathy; STR: Sight-threatening retinopathy;
eGFR: Estimated glomerular filtration rate; CPAP: Continuous positive airway
pressure; RCT: Randomised control trial; EDS: Excessive daytime sleepiness;
ESS: Epworth Sleepiness Scale; HbA1c: Haemoglobin A1c; ACR: Albumin/
creatinine ratio; SF-12: Short Form Health Survey; MNSI: Michigan Neuropathy
Screening Instrument; SF-MPQ: Short Form McGill Pain Questionnaire;
CAN: Cardiac autonomic neuropathy; MEQ: Morningness-Eveningness
Questionnaire; PSQI: Pittsburgh Sleep Quality Index; AE: Adverse event
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s40814-021-00817-z.
Additional file 1. Detailed description of the outcome measures and
assessments.
Acknowledgements
We acknowledge the Birmingham Clinical Trials Unit (BCTU) for trial
coordination, data management, and analysis and the Research Governance
team at University of Birmingham for governance and sponsor duties. We
acknowledge the support of the National Institute of Health Research Clinical
Antza et al. Pilot and Feasibility Studies            (2021) 7:80 Page 8 of 11
Research Network (NIHR CRN). The views expressed are those of the authors
and not necessarily those of the NHS, the NIHR, or the Department of Health
and Social Care.
Authors’ contributions
CA provided critical input into trial design and wrote the manuscript. AAT,
AA, BC, MN, ST, GS, SP, and RO conceptualised and designed the trial, helped
with statistics for the trial, and helped in writing the manuscript. The authors
read and approved the final manuscript.
Funding
The SLEEP T2D Study is funded by a Clinician Scientist Fellowship awarded
to the Chief Investigator by the National Institute for Health Research (CS-
2013-13-029).
The funder had no role in the design or the reporting of the study or any
other activity such as collection, management, analysis, and interpretation of
data; writing of the report; and the decision to submit the report for
publication.
All authors have read and approved the manuscript.
Availability of data and materials
Not applicable.
Declarations
Ethics approval and consent to participate
National Research Ethics Committee West Midlands – The Black Country,
reference 18/WM/0070.
The conduct of the study will be in accordance with the principles of Good
Clinical Practice. The participant’s written informed consent to participate in
the study will be obtained before any procedures relating to the study are
undertaken and after a full explanation has been given of the study, the
treatment options, and the manner of treatment allocation and
randomisation. Two Participant Information Sheets (PIS) will be provided to
facilitate this process, one for the study as a whole, and one for the RCT.
They will also stress that participation is voluntary and that the participant is
free to refuse to take part and may withdraw from the study at any time.
The participant will be given sufficient time to read the PIS and to discuss
their participation with others outside of the site research team. The
participant will be given the opportunity to ask questions prior to signing




The authors declare that they have no competing interests.
Author details
1Institute of Metabolism and Systems Research, University of Birmingham,
Birmingham, UK. 2Birmingham Clinical Trials Unit, College of Medical and
Dental Sciences, University of Birmingham, Birmingham, UK. 3Lung Function
& Sleep, University Hospitals Birmingham NHS Foundation Trust, Birmingham,
UK. 4Department of Respiratory Medicine, University Hospitals Coventry &
Warwickshire, Coventry, UK. 5Centre of Endocrinology Diabetes and
Metabolism, Birmingham Health Partners, Birmingham, UK. 6Department of
Diabetes and Endocrinology, University Hospitals NHS Foundation Trust,
Birmingham, UK.
Received: 1 September 2020 Accepted: 9 March 2021
References
1. Semelka M, Wilson J, Floyd R. Diagnosis and treatment of obstructive sleep
apnea in adults. Am Fam Physician. 2016;94(5):355–60.
2. White DP. Sleep-related breathing disorder.2. Pathophysiology of
obstructive sleep apnoea. Thorax. 1995;50(7):797–804. https://doi.org/10.113
6/thx.50.7.797.
3. Kapur VK, Auckley DH, Chowdhuri S, Kuhlmann DC, Mehra R, Ramar K,
Harrod CG. Clinical practice guideline for diagnostic testing for adult
obstructive sleep apnea: an American Academy of Sleep Medicine Clinical
practice guideline. J Clin Sleep Med. 2017;13(3):479–504. https://doi.org/10.
5664/jcsm.6506.
4. Senaratna CV, Perret JL, Lodge CJ, Lowe AJ, Campbell BE, Matheson MC,
Hamilton GS, Dharmage SC. Prevalence of obstructive sleep apnea in the
general population: a systematic review. Sleep Med Reviews. 2017;34:70–81.
https://doi.org/10.1016/j.smrv.2016.07.002.
5. Quan SF, Howard BV, Iber C, Kiley JP, Nieto FJ, O’Connor GT, et al. The
Sleep Heart Health Study: design, rationale, and methods. Sleep. 1997;
20(12):1077–85.
6. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of
sleep-disordered breathing among middle-aged adults. New England J
Med. 1993;328(17):1230–5. https://doi.org/10.1056/NEJM199304293281704.
7. Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased
prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013;
177(9):1006–14. https://doi.org/10.1093/aje/kws342.
8. Kendzerska T, Gershon AS, Hawker G, Tomlinson G, Leung RS. Obstructive
sleep apnea and incident diabetes. A historical cohort study. Am J
Respiratory Critical Care Med. 2014;190(2):218–25. https://doi.org/10.1164/
rccm.201312-2209OC.
9. Marshall NS, Wong KK, Phillips CL, Liu PY, Knuiman MW, Grunstein RR. Is
sleep apnea an independent risk factor for prevalent and incident diabetes
in the Busselton Health Study? J Clin Sleep Med. 2009;5(1):15–20.
10. Nagayoshi M, Punjabi NM, Selvin E, Pankow JS, Shahar E, Iso H, Folsom AR,
Lutsey PL. Obstructive sleep apnea and incident type 2 diabetes. Sleep Med.
2016;25:156–61. https://doi.org/10.1016/j.sleep.2016.05.009.
11. Subramanian A, Adderley NJ. Risk of incident obstructive sleep apnea
among patients with type 2 diabetes. Diab Care. 2019;42(5):954-63.
12. Einhorn D, Stewart DA, Erman MK, Gordon N, Philis-Tsimikas A, Casal E.
Prevalence of sleep apnea in a population of adults with type 2 diabetes
mellitus. Endocrine Practice. 2007;13(4):355–62. https://doi.org/10.4158/
EP.13.4.355.
13. Foster GD, Sanders MH, Millman R, Zammit G, Borradaile KE, Newman AB,
Wadden TA, Kelley D, Wing RR, Pi Sunyer FX, Darcey V, Kuna ST, for the
Sleep AHEAD Research Group. Obstructive sleep apnea among obese
patients with type 2 diabetes. Diabetes Care. 2009;32(6):1017–9. https://doi.
org/10.2337/dc08-1776.
14. Schober AK, Neurath MF, Harsch IA. Prevalence of sleep apnoea in diabetic
patients. Clin Respiratory J. 2011;5(3):165–72. https://doi.org/10.1111/j.1752-
699X.2010.00216.x.
15. Tahrani AA, Zeng W, Shakher J, Piya MK, Hughes S, Dubb K, Stevens MJ.
Cutaneous structural and biochemical correlates of foot complications in
high-risk diabetes. Diabetes Care. 2012;35(9):1913–8. https://doi.org/10.2337/
dc11-2076.
16. West SD, Nicoll DJ, Stradling JR. Prevalence of obstructive sleep apnoea in
men with type 2 diabetes. Thorax. 2006;61(11):945–50. https://doi.org/10.113
6/thx.2005.057745.
17. Laaban JP, Daenen S, Leger D, Pascal S, Bayon V, Slama G, et al. Prevalence and
predictive factors of sleep apnoea syndrome in type 2 diabetic patients.
Diabetes Metab. 2009;35(5):372–7. https://doi.org/10.1016/j.diabet.2009.03.007.
18. Amin A, Ali A, Altaf QA, Piya MK, Barnett AH, Raymond NT, Tahrani AA.
Prevalence and associations of obstructive sleep apnea in South Asians and
White Europeans with type 2 diabetes: a cross-sectional study. J Clin Sleep
Med. 2017;13(4):583–9. https://doi.org/10.5664/jcsm.6548.
19. Pillai A, Warren G, Gunathilake W, Idris I. Effects of sleep apnea severity on
glycemic control in patients with type 2 diabetes prior to continuous
positive airway pressure treatment. Diabetes Technol Ther. 2011;13(9):945–9.
https://doi.org/10.1089/dia.2011.0005.
20. Brownrigg JR, Hughes CO, Burleigh D, Karthikesalingam A, Patterson BO,
Holt PJ, et al. Microvascular disease and risk of cardiovascular events among
individuals with type 2 diabetes: a population-level cohort study. Lancet
Diabetes Endocrinol. 2016;4(7):588–97. https://doi.org/10.1016/S2213-8587(1
6)30057-2.
21. NHS. Diabetes: cases and costs predicted to rise. 2012.
22. Brownlee M. Biochemistry and molecular cell biology of diabetic
complications. Nature. 2001;414(6865):813–20. https://doi.org/10.1038/414813a.
23. Brownlee M. The pathobiology of diabetic complications: a unifying
mechanism. Diabetes. 2005;54(6):1615–25. https://doi.org/10.2337/diabetes.
54.6.1615.
24. Tahrani AA, Askwith T, Stevens MJ. Emerging drugs for diabetic neuropathy.
Expert Opin Emerg Drugs. 2010;15(4):661–83. https://doi.org/10.1517/1472
8214.2010.512610.
Antza et al. Pilot and Feasibility Studies            (2021) 7:80 Page 9 of 11
25. Allahdadi KJ, Duling LC, Walker BR, Kanagy NL. Eucapnic intermittent
hypoxia augments endothelin-1 vasoconstriction in rats: role of PKCdelta.
Am J Physiol Heart Circ Physiol. 2008;294(2):H920–7. https://doi.org/10.11
52/ajpheart.01264.2007.
26. Arnardottir ES, Mackiewicz M, Gislason T, Teff KL, Pack AI. Molecular
signatures of obstructive sleep apnea in adults: a review and perspective.
Sleep. 2009;32(4):447–70. https://doi.org/10.1093/sleep/32.4.447.
27. Atkeson A, Yeh SY, Malhotra A, Jelic S. Endothelial function in obstructive
sleep apnea. Prog Cardiovasc Dis. 2009;51(5):351–62. https://doi.org/10.1016/
j.pcad.2008.08.002.
28. Barcelo A, Miralles C, Barbe F, Vila M, Pons S, Agusti AG. Abnormal lipid
peroxidation in patients with sleep apnoea. Eur Respiratory J. 2000;16(4):
644–7. https://doi.org/10.1034/j.1399-3003.2000.16d13.x.
29. Carpagnano GE, Kharitonov SA, Resta O, Foschino-Barbaro MP, Gramiccioni
E, Barnes PJ. 8-Isoprostane, a marker of oxidative stress, is increased in
exhaled breath condensate of patients with obstructive sleep apnea after
night and is reduced by continuous positive airway pressure therapy. Chest.
2003;124(4):1386–92. https://doi.org/10.1378/chest.124.4.1386.
30. de la Pena M, Barcelo A, Barbe F, Pierola J, Pons J, Rimbau E, et al.
Endothelial function and circulating endothelial progenitor cells in patients
with sleep apnea syndrome. Respiration. 2008;76(1):28–32. https://doi.org/1
0.1159/000109643.
31. Dyugovskaya L, Lavie P, Lavie L. Increased adhesion molecules expression
and production of reactive oxygen species in leukocytes of sleep apnea
patients. Am J Respiratory Critical Care Med. 2002;165(7):934–9. https://doi.
org/10.1164/ajrccm.165.7.2104126.
32. Jelic S, Lederer DJ, Adams T, Padeletti M, Colombo PC, Factor PH, le Jemtel
TH. Vascular inflammation in obesity and sleep apnea. Circulation. 2010;
121(8):1014–21. https://doi.org/10.1161/CIRCULATIONAHA.109.900357.
33. Lavie L. Oxidative stress--a unifying paradigm in obstructive sleep apnea
and comorbidities. Prog Cardiovasc Dis. 2009;51(4):303–12. https://doi.org/1
0.1016/j.pcad.2008.08.003.
34. Lavie L, Vishnevsky A, Lavie P. Evidence for lipid peroxidation in obstructive
sleep apnea. Sleep. 2004;27(1):123–8.
35. Minoguchi K, Yokoe T, Tanaka A, Ohta S, Hirano T, Yoshino G, et al.
Association between lipid peroxidation and inflammation in obstructive
sleep apnoea. Eur Respiratory J. 2006;28(2):378–85. https://doi.org/10.1183/
09031936.06.00084905.
36. Peled N, Shitrit D, Bendayan D, Peled E, Kramer MR. Association of elevated
levels of vascular endothelial growth factor in obstructive sleep apnea
syndrome with patient age rather than with obstructive sleep apnea
syndrome severity. Respiration. 2007;74(1):50–5. https://doi.org/10.1159/
000095675.
37. Rangemark C, Hedner JA, Carlson JT, Gleerup G, Winther K. Platelet function
and fibrinolytic activity in hypertensive and normotensive sleep apnea
patients. Sleep. 1995;18(3):188–94. https://doi.org/10.1093/sleep/18.3.188.
38. Saarelainen S, Lehtimaki T, Jaak-kola O, Poussa T, Nikkila M, Solakivi T, et al.
Autoantibodies against oxidised low-density lipoprotein in patients with
obstructive sleep apnoea. Clin Chem Lab Med. 1999;37(5):517–20.
39. Schulz R, Hummel C, Heinemann S, Seeger W, Grimminger F. Serum levels
of vascular endothelial growth factor are elevated in patients with
obstructive sleep apnea and severe nighttime hypoxia. Am J Respiratory
Critical Care Med. 2002;165(1):67–70. https://doi.org/10.1164/ajrccm.165.1.21
01062.
40. Schulz R, Mahmoudi S, Hattar K, Sibelius U, Olschewski H, Mayer K, et al.
Enhanced release of superoxide from polymorphonuclear neutrophils in
obstructive sleep apnea. Impact of continuous positive airway pressure
therapy. Am J Respiratory Critical Care Med. 2000;162(2 Pt 1):566–70.
https://doi.org/10.1164/ajrccm.162.2.9908091.
41. Tan KC, Chow WS, Lam JC, Lam B, Bucala R, Betteridge J, et al. Advanced
glycation endproducts in nondiabetic patients with obstructive sleep apnea.
Sleep. 2006;29(3):329–33. https://doi.org/10.1093/sleep/29.3.329.
42. Tasali E, Ip MS. Obstructive sleep apnea and metabolic syndrome:
alterations in glucose metabolism and inflammation. Proc Am Thorac Soc.
2008;5(2):207–17. https://doi.org/10.1513/pats.200708-139MG.
43. Valipour A, Litschauer B, Mittermayer F, Rauscher H, Burghuber OC, Wolzt M.
Circulating plasma levels of vascular endothelial growth factor in patients
with sleep disordered breathing. Respir Med. 2004;98(12):1180–6. https://doi.
org/10.1016/j.rmed.2004.04.009.
44. Xu W, Chi L, Row BW, Xu R, Ke Y, Xu B, Luo C, Kheirandish L, Gozal D, Liu R.
Increased oxidative stress is associated with chronic intermittent hypoxia-
mediated brain cortical neuronal cell apoptosis in a mouse model of sleep
apnea. Neuroscience. 2004;126(2):313–23. https://doi.org/10.1016/j.
neuroscience.2004.03.055.
45. Yamauchi M, Nakano H, Maekawa J, Okamoto Y, Ohnishi Y, Suzuki T, Kimura
H. Oxidative stress in obstructive sleep apnea. Chest. 2005;127(5):1674–9.
https://doi.org/10.1378/chest.127.5.1674.
46. Tahrani AA, Ali A, Raymond NT, Begum S, Dubb K, Altaf QA, Piya MK,
Barnett AH, Stevens MJ. Obstructive sleep apnea and diabetic nephropathy:
a cohort study. Diabetes Care. 2013;36(11):3718–25. https://doi.org/10.2337/
dc13-0450.
47. Tahrani A, Dodson P, Ali A, Altaf Q, Wharton H, Raymond NT, et al.
Obstructive sleep apnoea is associated with sight threatening retinopathy
and predicts the development of preproliferative and proliferative
retinopathy in patients with type 2 diabetes: a longitudinal analysis. Eur J
Ophthalmol. 2013;23(3):449.
48. Koga S, Ikeda S, Yasunaga T, Nakata T, Maemura K. Effects of nasal
continuous positive airway pressure on the glomerular filtration rate in
patients with obstructive sleep apnea syndrome. Internal Med. 2013;52(3):
345–9.
49. Pinto VL SS. Continuous positive airway pressure (CPAP) [Updated 2019 May
11]. StatPearls [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK482178/.
50. Excellence NIfHaC. Continuous positive airway pressure for the treatment of
obstructive sleep apnoea/hypopnoea syndrome. NICE technology appraisal
guidance 139. 2008.
51. McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, et al. CPAP for
Prevention of Cardiovascular Events in Obstructive Sleep Apnea. New
England J Med. 2016;375(10):919–31. https://doi.org/10.1056/NEJMoa1
606599.
52. McMillan A, Bratton DJ, Faria R, Laskawiec-Szkonter M, Griffin S, Davies RJ,
Nunn AJ, Stradling JR, Riha RL, Morrell MJ, PREDICT Investigators.
Continuous positive airway pressure in older people with obstructive sleep
apnoea syndrome (PREDICT): a 12-month, multicentre, randomised trial.
Lancet Respiratory Med. 2014;2(10):804–12. https://doi.org/10.1016/S2213-2
600(14)70172-9.
53. West SD, Prudon B, Hughes J, Gupta R, Mohammed SB, Gerry S, et al.
Continuous positive airway pressure effect on visual acuity in patients with
type 2 diabetes and obstructive sleep apnoea: a multicentre randomised
controlled trial. Eur Respir J. 2018;52(4):1801177. https://doi.org/10.1183/13
993003.01177-2018. Print 2018 Oct.
54. Berry RB, Sriram P. Auto-adjusting positive airway pressure treatment for
sleep apnea diagnosed by home sleep testing. J Clin sleep Med. 2014;
10(12):1269–75.
55. Batool-Anwar S, Goodwin JL, Drescher AA, Baldwin CM, Simon RD, Smith
TW, Quan SF. Impact of CPAP on activity patterns and diet in patients with
obstructive sleep apnea (OSA). J Clin Sleep Med. 2014;10(5):465–72. https://
doi.org/10.5664/jcsm.3686.
56. Lee IS, Bardwell W, Ancoli-Israel S, Loredo JS, Dimsdale JE. Effect of three
weeks of continuous positive airway pressure treatment on mood in
patients with obstructive sleep apnoea: a randomized placebo-controlled
study. Sleep medicine. 2012;13(2):161–6. https://doi.org/10.1016/j.sleep.2011.
09.005.
57. Barbe F, Duran-Cantolla J, Sanchez-de-la-Torre M, Martinez-Alonso M,
Carmona C, Barcelo A, et al. Effect of continuous positive airway pressure on
the incidence of hypertension and cardiovascular events in nonsleepy
patients with obstructive sleep apnea: a randomized controlled trial. JAMA.
2012;307(20):2161–8. https://doi.org/10.1001/jama.2012.4366.
58. Craig SE, Kohler M, Nicoll D, Bratton DJ, Nunn A, Davies R, Stradling J.
Continuous positive airway pressure improves sleepiness but not calculated
vascular risk in patients with minimally symptomatic obstructive sleep
apnoea: the MOSAIC randomised controlled trial. Thorax. 2012;67(12):1090–
6. https://doi.org/10.1136/thoraxjnl-2012-202178.
59. Myhill PC, Davis WA, Peters KE, Chubb SA, Hillman D, Davis TM. Effect of
continuous positive airway pressure therapy on cardiovascular risk factors in
patients with type 2 diabetes and obstructive sleep apnea. J Clin Endocrinol
Metab. 2012;97(11):4212–8. https://doi.org/10.1210/jc.2012-2107.
60. Tamura A, Kawano Y, Watanabe T, Kadota J. Obstructive sleep apnea
increases hemoglobin A1c levels regardless of glucose tolerance status.
Sleep Med. 2012;13(8):1050–5. https://doi.org/10.1016/j.sleep.2012.04.007.
61. Lee SWH, Ng KY, Chin WK. The impact of sleep amount and sleep quality
on glycemic control in type 2 diabetes: a systematic review and meta-
Antza et al. Pilot and Feasibility Studies            (2021) 7:80 Page 10 of 11
analysis. Sleep Med Reviews. 2017;31:91–101. https://doi.org/10.1016/j.smrv.2
016.02.001.
62. Chirwa S, Nwabuisi CR, Ladson GM, Korley L, Whitty JE, Atkinson R, et al.
Poor sleep quality is associated with higher hemoglobin A1c in pregnant
women: a pilot observational study. Int J Environ Res Public Health. 2018;
15(10):2287. https://doi.org/10.3390/ijerph15102287.
63. Whitaker KM, Lutsey PL, Ogilvie RP, Pankow JS, Bertoni A, Michos ED, et al.
Associations between polysomnography and actigraphy-based sleep indices
and glycemic control among those with and without type 2 diabetes: the
Multi-Ethnic Study of Atherosclerosis. Sleep. 2018;41(11):zsy172. https://doi.
org/10.1093/sleep/zsy172.
64. Sakamoto R, Yamakawa T. Association of usual sleep quality and glycemic
control in type 2 diabetes in Japanese: a cross sectional study. Sleep Food
Registry Kanagawa (SOREKA). PLoS One. 2018;13(1):e0191771. https://doi.
org/10.1371/journal.pone.0191771. eCollection 2018.
65. Hur MH, Lee MK, Seong K, Hong JH. Deterioration of sleep quality
according to glycemic status; 2020.
66. Franke FJ, Arzt M, Kroner T, Gorski M, Heid IM, Böger CA, Jung B, Zeman F,
Stadler S, DIACORE Study Group. Daytime napping and diabetes-associated
kidney disease. Sleep Med. 2019;54:205–12. https://doi.org/10.1016/j.sleep.2
018.10.034.
67. Harding S, Greenwood R, Aldington S, Gibson J, Owens D, Taylor R, Kohner
E, Scanlon P, Leese G, The Diabetic Retinopathy Grading and Disease
Management Working Party. Grading and disease management in national
screening for diabetic retinopathy in England and Wales. Diabet Med. 2003;
20(12):965–71. https://doi.org/10.1111/j.1464-5491.2003.01077.x.
68. National Institute of Health Research (NIHR). Guidance on applying for




Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Antza et al. Pilot and Feasibility Studies            (2021) 7:80 Page 11 of 11
